BerGenBio reports second quarter and half year 2022 financial results and provides business update
- Commenced bemcentinib Phase 2b trial in hospitalized COVID-19 patients - - Initiation of Phase 1a/2b STK11 mutated NSCLC trial planned for 2H22 - - BerGenBio to host conference call and webcast today at 10:00 AM CEST/4:00 AM EDT - BERGEN, Norway, August 23, 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the second quarter and half year ended June 30, 2022 and provided a business update. “The prioritization of